Formestane: an effective first-line endocrine treatment for advanced breast cancer

Nicoletta Zilembo, Emilio Bajetta, Cristina Noberasco, Roberto Buzzoni, Giovanni Vicario, Aldo Bono, Alberto Laffranchi, Giuseppa Biasi, Stella Dolci, Ettore Bichisao

Research output: Contribution to journalArticlepeer-review


Formestane, a new selective aromatase inhibitor devoid of severe side-effects, has been shown to be active in patients with advanced breast cancer. To investigate the clinical activity and endocrinological effects of formestane as a first-line treatment, 52 patients were administered two different doses: 24 received 250 mg formestane and 28 received 500 mg formestane i.m. fortnightly. All of the patients had a performance status of 2 or less (ECOG scale), 34 (65%) had a disease-free interval of at least 2 years and 21 (40%) were both oestrogen-receptor- and progesterone-receptor-positive; 20 patients received hormone and 13 received chemotherapeutical adjuvant treatment. Objective responses were obtained in 8 patients in the 250-mg group (33%; 95% CI: 14%-52%) and in 13 patients in the 500-mg group (46%;, 95% CI.: 28%-64%). The median response duration in the two groups was respectively 11 and 12 months. E2 serum levels of oestradiol had significantly (P

Original languageEnglish
Pages (from-to)378-382
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Issue number6
Publication statusPublished - Jun 1995


  • Aromatase inhibitors
  • Breast neoplasm
  • Formestane
  • Hormonal treatment
  • Postmenopause

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Formestane: an effective first-line endocrine treatment for advanced breast cancer'. Together they form a unique fingerprint.

Cite this